Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of pharmacological and toxicological methods

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vascn.2011.02.002PMID 21376127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

  2007cited by this paper
• The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.

  2006cited by this paper
• MMP Induction and Inhibition in Myocardial Infarction

  2004cited by this paper
• Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.

  2003cited by this paper
• Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3

  2003cited by this paper
• Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice.

  2001cited by this paper
• Matrix metalloproteinases: biologic activity and clinical implications.

  2000cited by this paper
• Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

  2000cited by this paper
• Marimastat: the clinical development of a matrix metalloproteinase inhibitor

  2000cited by this paper
• Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.

  2000cited by this paper
• Preclinical and Clinical Studies of MMP Inhibitors in Cancer

  1999cited by this paper
• Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

  1998cited by this paper
• Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor

  1998cited by this paper
• Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

  1998cited by this paper
• Early development of synchronized walking on the rotorod in rats. Effects of training and handling.

  1998cited by this paper
• A simple, sensitive, and objective method for early assessment of acrylamide neuropathy in rats.

  1977cited by this paper

• Discovery of Novel Selenocyanate Derivatives as Histone Deacetylase 6 Inhibitors for the Treatment of Hepatocellular Carcinoma.

  2026cites this paper
• Selective bacterial proteolysis in periodontal disease: Molecular mechanisms and therapeutic implications, a narrative review.

  2025cites this paper
• Selected Biomarkers of Tick-Borne Encephalitis: A Review

  2021cites this paper
• Bioguided Fractionation of Local Plants against Matrix Metalloproteinase9 and Its Cytotoxicity against Breast Cancer Cell Models: In Silico and In Vitro Study

  2020cites this paper
• Selective inhibition of matrix metalloproteinase 10 (MMP10) with a single-domain antibody

  2020cites this paper
• Role of matrix metalloproteinases 2 and 9 in the development of frozen shoulder: human data and experimental analysis in a rat contracture model.

  2019cites this paper
• Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis.

  2018cites this paper
• Delivery of Agents Into Articular Cartilage With Electric Spark-Induced Sound Waves

  2018cites this paper
• Nonproliferative and Proliferative Lesions of the Rat and Mouse Skeletal Tissues (Bones, Joints, and Teeth)

  2016cites this paper
• Inclusion of Safety Pharmacology Endpoints in Repeat-Dose Toxicity Studies.

  2015cites this paper
• On the predictive utility of animal models of osteoarthritis

  2015cites this paper
• Angiogenesis During Tumor Proliferation and Cell Invasion

  2015cites this paper
• The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics.

  2014cites this paper
• Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.

  2014cites this paper
• CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine

  2013cites this paper
• The role of microRNAs in the pathogenesis of MMPi-induced skin fibrodysplasia

  2013cites this paper
• Functional assessments in repeat-dose toxicity studies: the art of the possible

  2013cites this paper
• Innovation in safety pharmacology testing.

  2011cites this paper
• Principles of Safety Pharmacology

  2008cites this paper